Novel bioinformatics approaches for biological inference from comparative genomics data. Unlocking the potential of the human and other genome sequences depends almost entirely upon comparative genomics techniques. We will develop powerful bioinformatic models, implemented as high-performance computing solutions, for the examination of gene sequences. Improving these models, which represent the initial building block for all comparative genomics techniques, will be beneficial across genomics dep ....Novel bioinformatics approaches for biological inference from comparative genomics data. Unlocking the potential of the human and other genome sequences depends almost entirely upon comparative genomics techniques. We will develop powerful bioinformatic models, implemented as high-performance computing solutions, for the examination of gene sequences. Improving these models, which represent the initial building block for all comparative genomics techniques, will be beneficial across genomics dependent industries. A major outcome from this work will be an integrated software/hardware product optimised for statistical examination of very large-scale genomics data.Read moreRead less
Molecular response to interferon beta treatment in multiple sclerosis. Inteferon beta (IFNb) is the frontline drug for treatment of multiple sclerosis. However, in many patients this expensive drug provides no benefit, resulting in unnecessary, uncontrolled disease progression, and in a waste of many millions of dollars each year. A common explanation for this treatment failure is the development of neutralising antibodies (NABs). We will establish the prevalence and effects of NABs in Austra ....Molecular response to interferon beta treatment in multiple sclerosis. Inteferon beta (IFNb) is the frontline drug for treatment of multiple sclerosis. However, in many patients this expensive drug provides no benefit, resulting in unnecessary, uncontrolled disease progression, and in a waste of many millions of dollars each year. A common explanation for this treatment failure is the development of neutralising antibodies (NABs). We will establish the prevalence and effects of NABs in Australian patients, use novel techniques to identify biomarkers for IFNb response, evaluate the diagnostic and therapeutic value of the biomarkers, and develop a new test for NABs. Tailored use of this drug, and possible new therapeutic targets, will result, benefiting the patient and community.Read moreRead less